Japan-based Takeda Pharmaceutical has entered a partnership with Cardurion Pharmaceuticals to develop new and advanced therapeutics for the treatment of cardiovascular diseases.
Cardurion is a newly formed US-based biotechnology company that focuses on the development of latest therapeutics to treat patients with heart failure or other cardiovascular diseases.
Under the new cardiovascular development partnership, Takeda will provide a 12-person cardiovascular research team from its Shonan, Japan site, to boost the discovery efforts made by Cardurion.
Takeda chief medical and scientific officer Dr Andrew Plump said: “The creation of this partnership with Cardurion follows Takeda’s strategy to leverage external innovation by placing selected assets and outstanding scientists into entrepreneurial environments.
“By leveraging the high level of therapeutic expertise at Takeda’s Shonan Research Centre to support drug discovery, we’re motivating scientists to come together to deliver on our promise of serving patients with existing unmet needs.”
Takeda will also provide the new company with fully equipped laboratory space, development resources and licences to range of preclinical-stage cardiovascular drug programmes.
Cardurion Pharmaceuticals chief executive officer Dr Daniel Bloomfield said: “This partnership demonstrates our shared commitment to developing transformative, novel therapies that can have a meaningful impact for the millions of people around the world suffering from heart disease.
“The scientific collaboration we’re establishing with Takeda will propel our preclinical efforts and ultimately help get important therapies into the hands of patients in need.”
Cardurion Pharmaceuticals is based in Cambridge, Massachusetts, US, and has research facilities in Shonan, Japan.
Image: Headquarters of Takeda Pharmaceutical Company in Chuo-ku, Osaka, Japan. Photo: courtesy of J o.